Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SLC5A7 | Q9GZV3 | 3/20 | 0.45 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
| ▸ | WDR5 | P61964 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4911611 | 0.81 | GAA (0.47) | EPHX2KMT2AGAAHPGD | |
| SCHEMBL3637309 | 0.81 | HDAC4 (0.46) | EPHX2GAAHPGD | |
| SCHEMBL4914729 | 0.78 | GAA (0.42) | EPHX2KMT2AGAAHPGD | |
| SCHEMBL4915833 | 0.78 | SMN1; SMN2 (0.43) | KAT6AKMT2AGAAHPGD | |
| SCHEMBL4916143 | 0.76 | SMN1; SMN2 (0.40) | POLBGAAHPGD | |
| SCHEMBL13753880 | 0.76 | EPHX2 (0.60) | EPHX2POLBSLC5A7KAT6AMEN1 | |
| SCHEMBL20588998 | 0.74 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL29828850 | 0.72 | KAT6A (0.60) | EPHX2POLBSLC5A7KAT6AMEN1 | |
| SCHEMBL13753855 | 0.71 | KAT6A (0.59) | EPHX2KAT6AMEN1KMT2ARAB9A | |
| SCHEMBL4914520 | 0.69 | TRPV1 (0.52) | POLBMEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242933-B2 | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-26 | — | — | US | disclosed |
| US-20080300260-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300260-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) | GRM2, GRIN2C, GRM1 | EPHX2 2119/4885POLB 4225/4885SLC5A7 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.